DENMARK – IT giant Infosys is set to acquire leading European consulting and technology company BASE life science for €110 million (approx. US$111 million).

According to a memorandum of understanding signed by the two companies, the deal is expected to close around Q2-FY23.

The acquisition of Denmark-headquartered BASE life science, one of the most rapidly growing consulting and technology partners in the health sciences industry, will strengthen Infosys’ capabilities in the life sciences segment and expand its presence in Europe.

The vertical of life sciences contributed 6.6 percent to Infosys’ overall revenues and saw year-on-year growth of 16.2 percent in terms of constant currency for the March quarter.

BASE will add a team of experts in domains like clinical, commercial, digital marketing, medical, regulatory, and quality know-how to Infosys.

Headquartered in Denmark, BASE has about 200 multidisciplinary industry experts across Denmark, Switzerland, UK, Germany, France, Italy, and a nearshore technology hub in Spain.

The company has always been on the forefront in terms of trending technologies and advancements. Besides, it has major thrust on artificial intelligence, data and the capacity to combine technology with business acumen to get improved health assessment.

Together with Infosys, BASE is expected to further expand its portfolio of expertise into Consumer Health, Animal Health, MedTech and Genomics segments.

Sharing his perspective, Ravi Kumar S, President, Infosys, said, “This acquisition augments Infosys’ deep life sciences expertise, and expands our footprint further in the Nordics region and across Europe, and scales our digital transformation capabilities with cloud-based industry solutions.

We are excited to welcome BASE life science and its leadership team into the Infosys family.”

Talking about the acquisition, Martin Woergaard, CEO, BASE life science said, “Over the last five years, BASE life science has delivered tremendous growth, and created a stellar life sciences consulting firm in Europe.

With Infosys as our catalyst, we will be able to accelerate our expansion internationally and create development opportunities for our people. Infosys is a solid, global technology leader, that is a perfect match for ensuring continuous success of BASE while sharing our common purpose and values.”

Diversifying expertise portfolio

Together with Infosys, BASE is expected to further expand its portfolio of expertise into Consumer Health, Animal Health, MedTech and Genomics segments.

BASE collaborates with leading software technology providers in the life sciences industry such as Veeva, IQVIA and Salesforce.

In 2021, Infosys through its subsidiary Infosys Consulting Pte. Ltd., acquired 100 percent share capital in Global Enterprise International Malaysia Sdn. Bhd. for 6 Mn Singapore Dollars (US$4.3 million).

According to the company’s statement with the exchanges, this acquisition was aimed at strengthening Infosys’ footprint in Malaysia, a crucial delivery and sales base for international clients in South East Asia.

Although the terms of the deal were not made public by the corporation, the company clearly stated its long-term vision for the Communications, Media, and Technology (CMT) vertical, which includes a platform-led transformation of the client’s customer and service experience.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE